Reborn Tech Scholar

Chapter 424 School-run Enterprise
Qin Yuanqing's work is still mainly based on scientific research. The school's school affairs are mainly handled by Xu Jiayi as his helper. He mainly focuses on the general direction. The usual internal affairs coordination of the 22-school alliance is also handed over to Xu Jiayi.

As the laboratories of other schools continued to be completed, the instruments and equipment donated by Qin Yuanqing to the 22-school alliance were gradually shipped out of the warehouse to those schools. Mizuki, returning to their respective schools, is gearing up for a big fight.

Although, Qin Yuanqing has repeatedly stated in public that he does not want to be the leader of some university, and Mizuki does not want to be the leader of the 22 school alliance.

However, Qin Yuanqing is the biggest sponsor of the 22nd school, and Shuimu University is also the No. 22 university in Shuimu University. It has already squeezed into the top ten universities in the world's latest ranking, and it just happens to be ranked tenth in the world.Shuimu University will continue to release joint scientific research projects, and in fact it is also the sponsor of the [-]-school alliance.

In this era where there is a mother who is a mother, Qin Yuanqing and Mizuki have actually become the leaders of the 22-school alliance, and they have a very large influence on the other 21 schools.

Qin Yuanqing went to the laboratory again. Although Qin Yuanqing became the head of Mizuki, the Automobile Research Institute, Aviation Engine Research Institute, and laboratories still maintained the original operating mode without any change.But now the director of the life laboratory is Yan Ning, and the chemistry laboratory is Wu Shihao. With two Nobel Prize winners in charge, the development of the laboratory is considered to be very smooth.

Although there are no more shocking achievements, various achievements have been produced continuously, the number of patents applied for is also constantly rising, and the value of the laboratory is constantly rising.

"Principal, the current mechanism of myocarditis, according to the feedback from [-] hospitals, is not out of the mechanism. The specific drug has entered the end of the first phase of clinical trials. At present, the performance of each volunteer is relatively good. .The tolerance test and pharmacokinetic test have entered the last batch of tests. It is planned to start the second phase of clinical trials next year. Currently, this matter is being communicated with the higher authorities to see if the progress of clinical trials can be accelerated, so as to strive for the specific drugs to be marketed as soon as possible. "Yan Ning reported on the research on myocarditis, relying on the myocarditis mechanism model and myocarditis peculiar factor that Qin Yuanqing worked out, making the laboratory a world leader in the field of heart disease in one fell swoop.

Qin Yuanqing nodded slightly.

The purpose of the first-phase clinical trial is mainly to study the human body's response and tolerance to new drugs, to explore safe and effective doses, to propose reasonable dosing regimens and precautions, to provide evidence for the dosing regimens of the second-phase clinical trials, and to evaluate the drug. The pharmacokinetics of absorption, distribution, metabolism and excretion in the body are studied.

It can be said that the first phase of clinical trials is very important.

However, no matter whether it is overseas or domestic, the first-phase clinical trials are often ignored, and the focus is on the second-phase clinical trials.

Of course, this kind of thing should not be put on the table. It is a black-box operation. It is rare for a laboratory to conduct research in conjunction with multiple hospitals, and to conduct sample experiments with a large number of volunteers. The duration is also sufficient.

If you want to shorten the time of clinical trials openly and advance the progress of clinical trials, there is still a way to go in China, and that is to seek the consent of the superiors. It only needs a meeting or an announcement to solve the problem.

It's just that domestic officials who can reach high positions are undoubtedly smart people. How can they not know the risks involved? To put it bluntly, no superior leader is willing to take this kind of risk and obediently send his own handle to himself In the hands of the enemy, he will be used by the enemy to remove himself from power at any time.

However, the laboratory is not comparable to other institutions. This achievement directly gave birth to three Nobel Prizes in Physiology or Medicine, and there were no mistakes in the first phase of clinical trials for so long. The possibility of entering the second phase of clinical trials is still very big.

"Principal, during this period of time, pharmaceutical companies have been coming to our door, looking for cooperation. Among them are the giants of overseas pharmaceutical companies, as well as the giants of domestic pharmaceutical companies. What do you mean?" Yan Ning hesitated for a moment, but she still asked.

Ever since she became the director of the life laboratory, Yan Ning has discovered that in addition to dealing with internal affairs, external affairs come one after another. For example, those giants of pharmaceutical companies are also very powerful. They hooked up with her in various ways, making her hard to guard against. , But some she can refuse, some she can't.

Although she is the director of the life laboratory, she is not qualified to decide such matters. After all, Qin Yuanqing holds 90% of the laboratory's shares and is the real owner of the laboratory.She is just a researcher, a manager.

Qin Yuanqing showed a pensive expression.

到了目前为止，华夏500强企业有198所市值上千亿，而其中有4家医药类企业进入华夏500强企业，有6家市值超千亿。恒瑞医药以2465亿元稳居医药上市公司市值的龙头，接下来则是1118亿元的康美药业、1082亿元的复星医药、1046亿元的石药集团、1043亿元的华夏生物制药、1031亿元的云南白药，都是刚刚过千亿。

From the top 500 companies in China, it can also be seen that in the form of China's industrial structure, high-end manufacturing and Internet companies are undoubtedly at the forefront, and their market value is the highest.

But there is no doubt that the potential of medicine is also very large. After all, with the increase of people's income, the requirements for medical level are also increasing day by day, and the demand for medicine will naturally increase, which means that the market is constantly expanding.

"I will handle this matter!" Qin Yuanqing said after pondering for a while.

After learning about the situation of the laboratory, Qin Yuanqing left. After returning to the office, Qin Yuanqing asked the vice principal in charge of the school and enterprise, Principal Huang, to visit his office.

Shuimu also has a school-enterprise group. It is the most important school-enterprise group in China. The "Shuimu Department" is very representative in terms of asset and liability structure, corporate governance structure, and business operation model. The final result of enterprise reform.

As early as 2015, the higher-level document on deepening the reform of the scientific and technological system and mechanism proposed that it is necessary to gradually realize the separation of high-end enterprises and subordinate enterprises. The cleaning and standardization of enterprises affiliated to colleges and universities, the efficiency of the system, and the promotion of colleges and universities to focus on the main business of teaching and scientific research.

The scale and social influence of Shuimu’s school-run enterprises are top-notch in China. In this school-enterprise reform, Shuimu University is not only a pioneer, but also the one that encounters the most difficulties.There is no way, as the number one university in China, Mizuki must take the lead in implementing the policy document.

But at the same time, it is not easy to reform these high-quality assets. After all, there are a large number of excellent teams who have led the development of the school and enterprise for many years. .

"Principal Huang, how is the school-enterprise reform going?" Qin Yuanqing asked.

"Hey, principal, this matter is really tricky. I am so busy that I am devastated. The difficulty is extremely great." Vice-principal Huang sighed and complained.

In 2003, Shuimu University integrated its industries and established a wholly-owned subsidiary, Shuimu Holdings.Shuimu University uses Shuimu Holdings as a platform to manage large-scale assets, covering industrial groups such as technology industry, innovative service, technology finance, creative industry, online education, etc., controlling Tongfang shares, Chengzhi shares, Ziguang shares, Ziguang Guowei, Eight A-share companies, including Tsinghua Unigroup, TusGuhan, TusEnvironment, and Chenan Technology, have a combined market capitalization of more than 8 billion yuan.According to this year's ranking, Shuimu Holdings ranks 5000th among the top 500 domestic enterprises this year.

It can be said that there are three major departments under Shuimu Holdings, that is, the Control Department, the Ziguang Department, and the Enlightenment Department.

Among them, the control capital refers to the listed companies directly controlled by Shuimu Holdings or its wholly-owned subsidiaries, including Tongfang, Chengzhi and Chenan Technology.Tsinghua Unigroup uses Tsinghua Unigroup as a platform to control Tsinghua Unigroup, Tsinghua Unigroup and Tsinghua Unigroup, and participates in many listed companies such as Wenyi Technology; Tusgroup controls TusGuhan and TusEnvironment through TusHoldings.In addition, Tsinghua Unigroup and TusHoldings respectively hold shares in a number of A-share companies, and Tongfang is the largest shareholder of Tellhow Technology.

Chengzhi Co., Ltd. is a high-tech listed company engaged in the production and sales of biological products and medicines controlled by Shuimu University.At present, Shuimu Holdings directly holds 11.76% of Chengzhi shares, and holds 33.44% through its wholly-owned subsidiary Chengzhi Kerong.Chenan Technology, another listed company of Shuimu Holdings, mainly relies on the technical advantages of Shuimu University Public Safety Research Institute to engage in the industrialization of public safety and emergency technology. Shuimu Holdings directly holds 8.16% of Chenan Technology. Through wholly-owned Subsidiary Mizuki Holdings holds 18.68% of the shares.

As for Tongfang shares, it has a special status in Shuimu Control's department because of its scale and popularity, it has greater advantages than the other two listed companies.Tongfang Co., Ltd. is the only A-share listed company directly controlled by Shuimu Holdings. Relying on the scientific research strength and talent platform of Shuimu University, Tongfang takes the road of combining production, education and research, and is positioned as a diversified and comprehensive technology industrial incubator, dedicated to China's high-tech achievements transformation and industrialization.As of now, Shuimu Holdings directly holds 25.75% of Tongfang shares, and Tsinghua Unigroup holds 2.35% of the shares.

Among the school-run enterprises of Shuimu University, the Ziguang Department is the largest and most complex.Tsinghua Unigroup is a leading digital infrastructure and service company, and is focusing on the development of electronic components and equipment manufacturing industries.As of the end of 2018, Tsinghua Unigroup had more than 4 employees worldwide, with total assets of about 2700 billion yuan.Tsinghua Unigroup is the third largest mobile phone chip design company in the world, accounting for more than 20% of the global SIM card chip market share.Shuimu Holdings holds 51% of Tsinghua Unigroup's shares, and the other 49% belongs to Jiankun Investment.The largest shareholder of Jiankun Investment is Zhao Weiguo, holding 70% of the shares, and the other two shareholders are Li Yi and Li Luyuan, each holding 15% of the shares.

TusHoldings is the platform of TusHoldings. The latter’s holding subsidiary TusKefu is the controlling shareholder of TusGuhan and TusEnvironment, with direct shareholding ratios of 29.44% and 16.56% respectively. TusKeFu also passed two wholly-owned subsidiaries The company holds 7.48% shares of Tus-Environment.TusHoldings is a technology investment holding group focusing on the field of technology services established on the basis of Shuimu University. It is the development, construction and operation management unit of Shuimu Science and Technology Park.According to the official website of TusHoldings, the total assets under management of the company exceed 2000 billion yuan.

In addition to Mizuki Holdings, there is also the "College Student Entrepreneurship Foundation" established by Shuimu University in the past ten years. The purpose of this foundation is to help Mizuki college students start their own businesses and provide venture capital to obtain this share. This part should not be underestimated. The company, calculated according to the market value of shares, has also expanded rapidly to 1800 billion yuan, and because the companies in which it participates are all in the stage of rapid expansion, the value of this part is still growing.

Qin Yuanqing also had some headaches. To be honest, many people were very resistant to the school-enterprise reform, because the school-run enterprises of Shuimu were all high-quality enterprises, and they were backed by Shuimu. Mizuki has sufficient funds these years and does not need to suck blood from these enterprises, which has led to the continuous development and growth of these enterprises.

However, a paper document from the superior forced Shuimu University to bite the bullet and implement it. It was just not long before the restructuring of Shuimu University encountered great difficulties and it was difficult to continue to implement it.

"Oh, I was still thinking about supporting Chengzhi and authorizing some patents of the life laboratory to Chengzhi. It seems that my thinking is too simple!" Qin Yuanqing said with a sigh.

Principal Huang turned pale with shock, and said with a wry smile: "Principal, don't do this. Now that we are the first and two universities, it is really troublesome to deal with school-run enterprises. If you support Chengzhi shares again, although you can Rapidly grow Chengzhi shares, but our troubles will be even greater, isn't this an open confrontation with the superiors."

Qin Yuanqing rubbed his temples. To be honest, Qin Yuanqing didn't think much of domestic pharmaceutical companies, no matter whether they were state-owned or private companies. The patent was granted to them, and Qin Yuanqing suspected that these pharmaceutical giants would not take advantage of the opportunity to expand themselves and improve their scientific research capabilities to enhance their strength, but to eat fat and have a mouth full of oil.

This is contrary to Qin Yuanqing's original intention. He hopes that Huaxia's pharmaceutical companies can focus on the world and improve their strength to fight against overseas pharmaceutical giants, instead of making Huaxia a place where overseas pharmaceutical giants wantonly poke excess profits.

Since entrusting it to a school-run enterprise is not feasible, and he does not want to cooperate with state-owned pharmaceutical giants or private pharmaceutical giants, Qin Yuanqing can't help but wonder if he should set up a pharmaceutical company by himself, and then use the laboratory's patents to grow step by step and become a pharmaceutical company. The new pharmaceutical giant.

Like Pfizer, it can become the world's pharmaceutical giant, not because the laboratory made a small blue pill by mistake, and has been invincible since then, relying on the small blue pill to conquer the world.

(End of this chapter)